

BOSTON SCIENTIFIC ANNOUNCES FIRST IMPLANT OF NEW DEVICE TO TREAT SUDDEN CARDIAC DEATH

Paris, France (3 March 2008) -- Boston Scientific Corporation (NYSE: BSX) today announced the first implant of its TELIGEN™ implantable cardioverter defibrillator (ICD). This device represents an entirely new platform to treat sudden cardiac death and is the result of a multi-year research and development effort to provide physicians enhanced clinical options for their patients.

When choosing a high-energy device, physicians often must make trade-offs among device size, battery longevity and features. The TELIGEN ICD is designed to eliminate those compromises.

“The TELIGEN ICD, even with its small size, offers extended longevity and comprehensive programming options that meet the needs of physicians and patients,” said Lieselotte van Erven, M.D., Leiden University Medical Center, Leiden, The Netherlands (Head of department Prof. M. J. Schalij). “The device offers me flexibility for delivering defibrillation to my patients and helps ensure that the right therapy is delivered at the appropriate time.”

The TELIGEN ICD is among the world’s smallest and thinnest high-energy devices at 31.5 cc, while less than 10 mm thick. It offers features based on significant engineering advances, including extended battery longevity, self-correcting software and improved programming technology. The TELIGEN ICD also offers SafetyCore™, a feature that in the unlikely event of a system error provides lifesaving shock therapy and basic pacing functionality.

Key features of the TELIGEN ICD include:

- Thinnest device available in the world, designed with patient comfort in mind
- Reverse Mode Switch™: designed to eliminate unnecessary ventricular pacing
- Quick Convert™: provides additional flexibility for patients to receive pacing therapy for ventricular tachycardias

“Our CRM team is refocused on delivering therapy systems that meet clinician needs for safety, reliability and better patient outcomes,” said Jim Tobin, President and Chief Executive Officer of Boston Scientific. “We have re-engineered the way we design, build, test and report on our technology. The TELIGEN ICD is a testament to the revitalisation of our CRM business and is one of many new products we plan to launch in 2008.”

The first implants were performed by the following physicians:

Dr. Siegmund Winter, Elisabethinen Linz, Linz, Austria

Prof. Rik Willems, UZ Leuven, Leuven, Belgium

Dr. med. Poul-Erik Bloch-Thomson, Gentofte Hospital, Hellerup, Denmark

Dr. med. Jürgen Vogt, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany

OA Dr. Johannes Sperzel, Kerckhoff-Klinik Bad Nauheim, Bad Nauheim, Germany

OA Dr. med. Claudius Hansen, Klinikum Kassel, Kassel, Germany

Prof. Dr. med. Bernd Lemke, Klinikum Lüdenscheid, Lüdenscheid, Germany

PD Dr. med. habil. Andreas Götte, Universitätsklinikum Magdeburg, Magdeburg, Germany

PD Dr. med. Rainer Gradaus, Uniklinikum Münster, Münster, Germany

Dr. Lieselot van Erven, Leiden University Medical Center, Leiden, The Netherlands

Dr. Luis Mont i Girbau, Hospital Clínic de Barcelona, Barcelona, Spain

Dr. Javier Alzuela, Hospital Clínico de Málaga, Málaga, Spain

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific-international.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, regulatory approval of our products, new product launches, competitive offerings, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialise, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of

these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Géraldine Varoqui
Boston Scientific PR Manager International
Tel: +49 2102 489 461
varoqui@bsci.com

OR

Tracy Paul
BSC press office
Tel: + 44 20 7413 3101
tpaul@medicalknowledgegroup.com